Highest-materiality recent filing
vTv Therapeutics upsizes ATM program to maximum authorized shares
Filed a prospectus supplement to increase shares offered under its at-the-market sales program to the full amount authorized.
Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026
Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
vTv Therapeutics posts updated investor presentation focused on diabetes pipeline
Slide deck titled 'Committed to Improving the Lives of People with Diabetes' posted for March 2026.
vTv Therapeutics posts updated investor slide presentation on February 26, 2026
Company posted updated investor presentation dated February 2026 on its website.
Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.
vTv Therapeutics lowers stockholder meeting quorum to 33.4%
Board amended Section 2.8 of Second Amended and Restated By-Laws on December 19, 2025.
vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026
Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.
vTv Therapeutics announces fireside chat at Morgan Stanley Healthcare Conference
Company participating in fireside chat on Sept 10, 2025 from 2:35 PM - 3:10 PM EST.
vTv Therapeutics raises up to $80M in private placement; initial close $65M on Sept 3
Raises up to $80M gross proceeds from private placement of 5,243,732 units at $15.265 per unit (or $15.255 with pre-funded warrant).
vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized
Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.
vTv Therapeutics stockholders elect seven directors and ratify Ernst & Young as auditor for 2025
All seven director nominees elected: Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, Daniel K. Spiegelman.
vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial
Michael Tung appointed EVP and CFO effective May 19, 2025; base salary $450,000, target bonus 40%.
vTv Therapeutics posts May 2025 investor presentation on website
Presentation posted on May 16, 2025 for use in investor and analyst meetings.
vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026
Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.
vTv Therapeutics appoints Barry K. Brown as interim principal financial officer
Barry K. Brown, 64, appointed interim principal financial officer effective April 11, 2025; continues as chief accounting officer.
Filing is a Reg FD disclosure of a slide deck used for meetings with investors and analysts.
vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025
Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.
FDA lifts clinical hold on vTv Therapeutics' cadisegliatin Phase 3 diabetes trial
FDA lifted clinical hold effective March 14, 2025; CATT1 trial to resume after protocol amendment.
vTv Therapeutics CFO Steven Tuch to resign effective March 21, 2025
Steven Tuch, EVP and CFO, informed company of resignation on Feb 24, 2025.
vTv Therapeutics posts updated investor presentation for January 2025
Company posted an updated slide presentation on its website on Jan 13, 2025.
vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues
Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.
vTv Therapeutics receives termination notice for ppar-δ license from OnKure; effective Jan 2025
OnKure (formerly Reneo) notified vTv LLC intent to terminate the December 2017 License Agreement for vTv's ppar-δ agonist program IP.
vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial
Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.
FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes
FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.
vTv Therapeutics expands Newsoara license globally for $20M upfront, up to $96M milestones
Second Amendment to License Agreement with Newsoara Biopharma expands original China license to global.
vTv Therapeutics stockholders elect seven directors and approve 2024 Equity Incentive Plan
At the June 11, 2024 annual meeting, stockholders elected Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard Nelson, Anne Phillips, Paul Sekhri, and Daniel Spiegelman as directors.
vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track
Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.
vTv Therapeutics regains Nasdaq MVLS compliance; listing continues
Nasdaq notified vTv Therapeutics on March 25, 2024 that it regained compliance with the $35M MVLS minimum.
vTv Therapeutics elects Anne Phillips as director; Fry and Weiner resign
Anne Phillips elected director effective March 13, 2024; will chair Compensation Committee and serve on Audit Committee.
vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial
Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.
On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.
On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately.
On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.
On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the “Company”), effective and contingent on the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the “2023 Annual Report”).
John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.
John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.
Max materiality 0.80 · Median 0.55 · Most common event other_material